[ Price : $8.95]
Sanofi says data from a Phase 2 study of amlitelimab misses its endpoint in adults with moderate-to-severe asthma, while promising...[ Price : $8.95]
Mural Oncology discontinues all clinical development of its lead drug candidate, nemvaleukin alfa based on disappointing results f...[ Price : $8.95]
FDA grants Click Therapeutics a de novo marketing authorization for its prescription digital therapeutic, CT-132, a prescription d...[ Price : $8.95]
FDA clears a TytoCare 510(k) for its Tyto Insights for Rhonchi Detection, an artificial intelligence-based device for detecting al...[ Price : $8.95]
Chinese medical school researchers who analyzed cancer drug surrogate endpoint approvals in the U.S. and China say China appears t...[ Price : $8.95]
Researchers say some issues need to be resolved if patient-reported outcomes are to be used as a surrogate in heart failure drug a...[ Price : $8.95]
Citing concerns raised by a vascular surgeon when he was a CDRH medical reviewer, Harmed Americans for Reform in Medical Device Sa...